Skip to main content

Advertisement

SpringerLink
Log in

The validity of 18F-GE180 as a TSPO imaging agent

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cumming P, Burgher B, Patkar O, et al. Sifting through the surfeit of neuroinflammation tracers. J Cereb Blood Flow Metab. 2018;38:204–24.

    Article  PubMed  Google Scholar 

  2. Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32:1–5.

    Article  CAS  PubMed  Google Scholar 

  3. Wadsworth H, Jones PA, Chau WF, et al. [(1)(8)F]GE-180: a novel fluorine-18 labelled PET tracer for imaging translocator protein 18 kDa (TSPO). Bioorg Med Chem Lett. 2012;22:1308–13.

    Article  CAS  PubMed  Google Scholar 

  4. Boutin H, Murray K, Pradillo J, et al. 18F-GE-180: a novel TSPO radiotracer compared to 11C-R-PK11195 in a preclinical model of stroke. Eur J Nucl Med Mol Imaging. 2015;42:503–11.

    Article  CAS  PubMed  Google Scholar 

  5. Chaney A, Cropper HC, Johnson EM, et al. (11)C-DPA-713 versus (18)F-GE-180: a preclinical comparison of TSPO-PET tracers to visualize acute and chronic neuroinflammation in a mouse model of ischemic stroke. J Nucl Med. 2018;60(1):122–28.

  6. Sridharan S, Lepelletier FX, Trigg W, et al. Comparative evaluation of three TSPO PET radiotracers in a LPS-induced model of mild neuroinflammation in rats. Mol Imaging Biol. 2017;19:77–89.

    Article  CAS  PubMed  Google Scholar 

  7. Fan Z, Calsolaro V, Atkinson RA, et al. Flutriciclamide (18F-GE180) PET: first-in-human PET study of novel third-generation in vivo marker of human translocator protein. J Nucl Med. 2016;57:1753–9.

    Article  CAS  PubMed  Google Scholar 

  8. Feeney C, Scott G, Raffel J, et al. Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain. Eur J Nucl Med Mol Imaging. 2016;43:2201–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Zanotti-Fregonara P, Pascual B, Rizzo G, et al. Head-to-head comparison of (11)C-PBR28 and (18)F-GE180 for quantification of the translocator protein in the human brain. J Nucl Med. 2018;59:1260–6.

    Article  CAS  PubMed  Google Scholar 

  10. Albert NL, Unterrainer M, Fleischmann DF, et al. TSPO PET for glioma imaging using the novel ligand 18F-GE-180: first results in patients with glioblastoma. Eur J Nucl Med Mol Imaging. 2017;44(13):2230–238.

  11. Unterrainer M, Fleischmann DF, Diekmann C, et al. Comparison of (18)F-GE-180 and dynamic (18)F-FET PET in high grade glioma: a double-tracer pilot study. Eur J Nucl Med Mol Imaging. 2018 Sep 22 [Epub ahead of print].

  12. Unterrainer M, Mahler C, Vomacka L, et al. TSPO PET with [(18)F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing-remitting multiple sclerosis. Eur J Nucl Med Mol Imaging. 2018;45:1423–31.

    Article  PubMed  Google Scholar 

  13. Vomacka L, Albert NL, Lindner S, et al. TSPO imaging using the novel PET ligand [(18)F]GE-180: quantification approaches in patients with multiple sclerosis. EJNMMI Res. 2017;7:89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Dickstein LP, Zoghbi SS, Fujimura Y, et al. Comparison of F-18- and C-11-labeled aryloxyanilide analogs to measure translocator protein in human brain using positron emission tomography. Eur J Nucl Med Mol Imaging. 2011;38:352–7.

    Article  CAS  PubMed  Google Scholar 

  15. Ikawa M, Lohith TG, Shrestha S, et al. 11C-ER176, a radioligand for 18-kDa translocator protein, has adequate sensitivity to robustly image all three affinity genotypes in human brain. J Nucl Med. 2017;58:320–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kreisl WC, Fujita M, Fujimura Y, et al. Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker. NeuroImage. 2010;49:2924–32.

    Article  CAS  PubMed  Google Scholar 

  17. Zanotti-Fregonara P, Zhang Y, Jenko KJ, et al. Synthesis and evaluation of translocator 18 kDa protein (TSPO) positron emission tomography (PET) radioligands with low binding sensitivity to human single nucleotide polymorphism rs6971. ACS Chem Neurosci. 2014;5:963–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Owen DR, Gunn RN, Rabiner EA, et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med. 2011;52:24–32.

    Article  CAS  PubMed  Google Scholar 

  19. Brown AK, Fujita M, Fujimura Y, et al. Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28: a PET radioligand to image inflammation. J Nucl Med. 2007;48:2072–9.

    Article  CAS  PubMed  Google Scholar 

  20. Gauberti M, Montagne A, Quenault A, Vivien D. Molecular magnetic resonance imaging of brain-immune interactions. Front Cell Neurosci. 2014;8:389.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Galldiks N, Ullrich R, Schroeter M, Fink GR, Jacobs AH, Kracht LW. Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging. 2010;37:84–92.

    Article  PubMed  Google Scholar 

  22. Pirotte B, Goldman S, Massager N, et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med. 2004;45:1293–8.

    CAS  PubMed  Google Scholar 

  23. van de Haar HJ, Burgmans S, Jansen JF, et al. Blood-brain barrier leakage in patients with early Alzheimer disease. Radiology. 2016;281:527–35.

    Article  Google Scholar 

  24. Montagne A, Zhao Z, Zlokovic BV. Alzheimer’s disease: a matter of blood-brain barrier dysfunction? J Exp Med. 2017;214:3151–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. van Assema DM, Lubberink M, Bauer M, et al. Blood-brain barrier P-glycoprotein function in Alzheimer’s disease. Brain. 2012;135:181–9.

    Article  PubMed  Google Scholar 

  26. Deo AK, Borson S, Link JM, et al. Activity of P-glycoprotein, a beta-amyloid transporter at the blood-brain barrier, is compromised in patients with mild Alzheimer disease. J Nucl Med. 2014;55:1106–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nantz National Alzheimer Center and Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX, 77030, USA

    Paolo Zanotti-Fregonara, Belen Pascual & Joseph C. Masdeu

  2. Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London, UK

    Mattia Veronese & Federico Turkheimer

  3. Department of Neurosurgery, Houston Methodist Hospital and Research Institute, Houston, TX, USA

    Robert C. Rostomily

Authors
  1. Paolo Zanotti-Fregonara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mattia Veronese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Belen Pascual
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert C. Rostomily
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Federico Turkheimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joseph C. Masdeu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Zanotti-Fregonara.

Ethics declarations

Conflict of interest

The authors declare they have no conflict of interest.

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zanotti-Fregonara, P., Veronese, M., Pascual, B. et al. The validity of 18F-GE180 as a TSPO imaging agent. Eur J Nucl Med Mol Imaging 46, 1205–1207 (2019). https://doi.org/10.1007/s00259-019-4268-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-019-4268-4

Search

Navigation